90% of Retirees Are Making This Savings Mistake. It Could Cost Them More Than They Think

Thank you for being a Global Market News subscriber.

90% of Retirees Are Making This Savings Mistake. It Could Cost Them More Than They Think

Millions of Americans spend decades worrying about whether they are saving enough for retirement. Then retirement arrives, and many make an unexpected mistake.

👉 Get the Full Details

Two Beaten-Down Dividend Stocks Yielding More Than 4% Could Be Setting Up for a 2027 Rebound

Treasury yields are crushing rate-sensitive stocks again, but Mizuho believes the selloff has created an unusually attractive setup in two housing REITs that now yield more than 4% and could enter 2027 with improving fundamentals.

👉 Read the Details

50 Years of Dividend Growth: These Elite Stocks Have Raised Their Payouts Through Every Crisis Since the 1970s

For investors seeking dependable income, few achievements in corporate America are more impressive than raising a dividend every year for at least half a century.

👉 Read the Details

Power of FDA Breakthrough Designation for Sepsis

The FDA doesn't grant Breakthrough Device Designation easily. It’s reserved for technologies with the potential to address life-threatening conditions, granting prioritized regulatory pathway.

Eliaz Therapeutics has earned this title for XGal-3®, an investigational sepsis device that is advancing toward human clinical trials next year.

This device targets Galectin-3, a protein that’s a key driver in the sepsis immune response, removing it directly from the bloodstream before organ failure sets in. Sepsis is a $100B/year problem, and there is currently no FDA-approved therapy that targets the cause. Not yet, at least.

Eliaz Therapeutics has 75+ patents across 30+ countries and a global collaboration with a world leader in medical technology, Terumo BCT.

And right now, you have the opportunity to back this technology before it potentially reaches the market.

👉 Invest in Eliaz Therapeutics Today